Comparison of the cost-effectiveness of sequential treatment with abaloparatide in US men and women at very high risk of fractures.

Hiligsmann M, Silverman SL, Singer AJ, Pearman L, Wang Y, Caminis J, Reginster JY

Aging clinical and experimental research30 Jan 2024Cited by 11 (Europe PMC)

PMID38289413PMCIDPMC10827834DOI10.1007/s40520-023-02682-7PepBankPUB-38289413

Summary

BackgroundOsteoporotic-related fractures represent an increasing burden to patients, health care systems and society.AimsThis study estimated cost-effectiveness of sequential treatment with abaloparatide (ABL) followed by alendronate (ALN) compared to relevant alternative strategies in US men and women aged 50 to 80 years at very high fracture risk (bone mineral density T-score ≤ - 2.5 and a recent fracture).MethodsA lifetime Markov-based microsimulation model was used to estimate healthcare costs and quality-adjusted life years (QALYs). Comparators were sequential treatment with unbranded teriparatide (TPTD)/ALN, generic ALN monotherapy, and no treatment. Analyses were conducted based on initial fracture site (hip, vertebral, or any fracture) and treatment efficacy data (derived from clinical trials or a recent network meta-analysis).ResultsFrom all analyses completed, sequential ABL/ALN demonstrated more QALYs for lower healthcare costs versus unbranded TPTD/ALN. No treatment was dominated (higher costs for less QALYs) versus ALN monotherapy. Sequential ABL/ALN resulted in favorable cost-effectiveness (at US threshold of $150,000/QALY) versus generic ALN monotherapy in men aged ≥ 50 years with any fracture type, women aged ≥ 65 years with any fracture type, and women aged ≥ 55 years having a hip or vertebral fracture.DiscussionSimilar cost-effectiveness of sequential ABL/ALN versus unbranded TPTD/ALN, ALN monotherapy, and no treatment was observed in both US men and women at very high fracture risk, with a moderate improvement in cost-effectiveness in men versus women and in patients with a hip or vertebral fracture.ConclusionsSequential therapy with ABL/ALN was cost-effective in US men and women at very high risk of fractures.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Abaloparatide (Tymlos).

01Computer modelNot a test of Abaloparatide (Tymlos) aloneIn silicoOther
In simulated high-fracture-risk US adults, abaloparatide followed by alendronate produced more QALYs than teriparatide followed by alendronate.
In plain wordsIn computer models, abaloparatide followed by alendronate produced more quality-adjusted life years than teriparatide followed by alendronate.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseQuality-adjusted life years
Study
n: not reported in source
Lifetime Markov-based microsimulation
Comparator
Teriparatide followed by alendronate
Outcome group
Cost-effectiveness · Musculoskeletal
Source sentences
Summary
From all analyses completed, sequential ABL/ALN demonstrated more QALYs for lower healthcare costs versus unbranded TPTD/ALN.
3 context sentences(design, population, supporting numbers)
Summary · context
A lifetime Markov-based microsimulation model was used to estimate healthcare costs and quality-adjusted life years (QALYs).
Summary · context
Comparators were sequential treatment with unbranded teriparatide (TPTD)/ALN, generic ALN monotherapy, and no treatment.
Summary · context
Analyses were conducted based on initial fracture site (hip, vertebral, or any fracture) and treatment efficacy data (derived from clinical trials or a recent network meta-analysis).
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Show in the study text Report a problemFND-3828941301
02Computer modelNot a test of Abaloparatide (Tymlos) aloneIn silicoOther
In simulated high-fracture-risk US adults, abaloparatide followed by alendronate cost less than teriparatide followed by alendronate.
In plain wordsIn computer models, abaloparatide followed by alendronate cost less than teriparatide followed by alendronate.
Peptide
Abaloparatide (Tymlos)
Outcome
DecreaseHealthcare costs
Study
n: not reported in source
Lifetime Markov-based microsimulation
Comparator
Teriparatide followed by alendronate
Outcome group
Cost-effectiveness · Musculoskeletal
Source sentences
Summary
From all analyses completed, sequential ABL/ALN demonstrated more QALYs for lower healthcare costs versus unbranded TPTD/ALN.
3 context sentences(design, population, supporting numbers)
Summary · context
A lifetime Markov-based microsimulation model was used to estimate healthcare costs and quality-adjusted life years (QALYs).
Summary · context
Comparators were sequential treatment with unbranded teriparatide (TPTD)/ALN, generic ALN monotherapy, and no treatment.
Summary · context
Analyses were conducted based on initial fracture site (hip, vertebral, or any fracture) and treatment efficacy data (derived from clinical trials or a recent network meta-analysis).
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Show in the study text Report a problemFND-3828941302
03Computer modelNot a test of Abaloparatide (Tymlos) aloneIn silicoOther
Modeled abaloparatide/alendronate met the $150,000/QALY threshold versus alendronate in men ≥50, women ≥65, and women ≥55 with hip or vertebral fractures.
In plain wordsIn computer models, abaloparatide followed by alendronate met the cost-effectiveness threshold versus alendronate in the specified age and fracture groups.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableCost-effectiveness versus alendronate
Study
n: not reported in source
Lifetime Markov-based microsimulation
Comparator
Generic alendronate monotherapy
Outcome group
Cost-effectiveness · Musculoskeletal
Source sentences
Summary
Sequential ABL/ALN resulted in favorable cost-effectiveness (at US threshold of $150,000/QALY) versus generic ALN monotherapy in men aged ≥ 50 years with any fracture type, women aged ≥ 65 years with any fracture type, and women aged ≥ 55 years having a hip or vertebral fracture.
3 context sentences(design, population, supporting numbers)
Summary · context
A lifetime Markov-based microsimulation model was used to estimate healthcare costs and quality-adjusted life years (QALYs).
Summary · context
Comparators were sequential treatment with unbranded teriparatide (TPTD)/ALN, generic ALN monotherapy, and no treatment.
Summary · context
Analyses were conducted based on initial fracture site (hip, vertebral, or any fracture) and treatment efficacy data (derived from clinical trials or a recent network meta-analysis).
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Show in the study text Report a problemFND-3828941303
04Computer modelNot a test of Abaloparatide (Tymlos) aloneIn silicoOther
Modeled sequential abaloparatide/alendronate had moderately better cost-effectiveness in men than women at very high fracture risk.
In plain wordsIn simulated male and female populations, sequential abaloparatide/alendronate had moderately better cost-effectiveness in the male population.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseCost-effectiveness by sex
Study
n: not reported in source
Lifetime Markov-based microsimulation
Comparator
Women
Outcome group
Cost-effectiveness · Musculoskeletal
Source sentences
Summary
Similar cost-effectiveness of sequential ABL/ALN versus unbranded TPTD/ALN, ALN monotherapy, and no treatment was observed in both US men and women at very high fracture risk, with a moderate improvement in cost-effectiveness in men versus women and in patients with a hip or vertebral fracture.
3 context sentences(design, population, supporting numbers)
Summary · context
A lifetime Markov-based microsimulation model was used to estimate healthcare costs and quality-adjusted life years (QALYs).
Summary · context
Comparators were sequential treatment with unbranded teriparatide (TPTD)/ALN, generic ALN monotherapy, and no treatment.
Summary · context
Analyses were conducted based on initial fracture site (hip, vertebral, or any fracture) and treatment efficacy data (derived from clinical trials or a recent network meta-analysis).
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Show in the study text Report a problemFND-3828941304
05Computer modelNot a test of Abaloparatide (Tymlos) aloneIn silicoOther
Modeled sequential abaloparatide/alendronate had moderately better cost-effectiveness in patients with hip or vertebral fractures.
In plain wordsIn computer models, sequential abaloparatide/alendronate had moderately better cost-effectiveness after hip or vertebral fractures than other fracture sites.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseCost-effectiveness by fracture site
Study
n: not reported in source
Lifetime Markov-based microsimulation
Comparator
Other initial fracture sites
Outcome group
Cost-effectiveness · Musculoskeletal
Source sentences
Summary
Similar cost-effectiveness of sequential ABL/ALN versus unbranded TPTD/ALN, ALN monotherapy, and no treatment was observed in both US men and women at very high fracture risk, with a moderate improvement in cost-effectiveness in men versus women and in patients with a hip or vertebral fracture.
3 context sentences(design, population, supporting numbers)
Summary · context
A lifetime Markov-based microsimulation model was used to estimate healthcare costs and quality-adjusted life years (QALYs).
Summary · context
Comparators were sequential treatment with unbranded teriparatide (TPTD)/ALN, generic ALN monotherapy, and no treatment.
Summary · context
Analyses were conducted based on initial fracture site (hip, vertebral, or any fracture) and treatment efficacy data (derived from clinical trials or a recent network meta-analysis).
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Show in the study text Report a problemFND-3828941305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.